Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (351-360 of 404) with videos related to

Pageof 41
Sort By:
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
European Urology Open Science|November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV CohortOndrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Pageof 41

Showing results (351-360 of 404) with videos related to

Sort By:
Pageof 41
The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.
Immunotherapy|January 20, 2025
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinationsMatilde Corianò, Alessandro Lazzarin, Michele Maffezzoli, et al.
Clinical and Experimental Medicine|November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 studyMatteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Frontiers in Immunology|May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Scientific Reports|March 15, 2025
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumabLorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, et al.
The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.
European Urology Open Science|November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV CohortOndrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Pageof 41